Jim Collins is a bioengineering professor at MIT, the Broad Institute and Harvard's Wyss Institute. He is one of the founders of synthetic biology and continues to push the field towards biomedical applications via translational research and spinouts such as Synlogic. His many advances in biotechnology and biomedicine include paper-based diagnostics for Zika and Ebola virus and programmable cells that act as diagnostics and therapeutics to detect and treat infections, rare genetic metabolic disorders and inflammatory bowel disease.
Collins also studies antibiotics to enhance our antibacterial arsenal and combat antibacterial resistance. He is proud of his many trainees who have gone on to make the world a better place.
Imagine, for a moment, living in a world where getting a cut could be life-threatening. That’s exactly what would happen if our antibiotics lose their ability to treat bacterial infections. Learn more about antibiotic resistance in bacteria and what Jim Collins and his team at MIT are doing to identify effective new drugs.
Continue reading